News

Newsletter

News on apostille of letters-patent retroactively affected by the Direct Plea of Unconstitutionality 5,529

On February 8th, 2022, the Brazilian Patent Office reported the decision to apostille letters-patent when the patent protects subject-matter going beyond the limits of the pharmaceutical area and/or health products/equipment for application in humans.

When the patent concomitantly encompasses subject-matter related to the pharmaceutical area and/or health products/equipment for application in humans and others not related to these technical areas, the apostille will take place as follows:

  1. For patents granted with the 10-year term counted as from their granting, the BPTO will maintain this term of protection, except for the subject-matter related to the pharmaceutical area and/or health products/equipment for use in humans, term of which will be 20 years counted as from their filing date;
    .
  2. The letter-patent will be rectified to include the apostille through the publication of the dispatch 16.3;
    ..
  3. The BPTO will produce an internal document justifying the rectification made. Said document will not be made publicly available, but it may be provided to interested parties upon request to the BPTO;
    .
  4. The extinction will be published taking into account the longest patent term, albeit part of the subject-matter related to pharmaceutical products and health products/equipment for application in humans will have its extinction before this date, as apostilled in the letter-patent;
    .
  5. Annuities must be paid considering the longest patent term.

.

In case you need further information on this topic, we are at your disposal by means of email: mail@kasznarleonardos.com.

Back

Last related news

August 16, 2022

Brazilian National Health Surveillance Agency (ANVISA) decides to ban Carbendazim

On August 8th, 2022, during the 12th Extraordinary Public Meeting of DICOL, ANVISA’s Collegiate Board of Directors announced the completion of the toxicological Brazilian National Health Surveillance Agency (ANVISA) decides to ban Carbendazim

Ler notícia

July 19, 2022

Carbendazim toxicological revaluation about to be completed by ANVISA

In December 2019, ANVISA started the process of toxicological revaluation of the Active Ingredient (AI) Carbendazim, as signs of toxicity were identified Carbendazim toxicological revaluation about to be completed by ANVISA

Ler notícia

July 6, 2022

Compulsory license: patent owners in Brazil are under no obligation to provide know-how and raw materials

Good news for patent owners in Brazil: the National Congress has upheld the President’s veto n° 48/2021, which prevented those who had their Compulsory license: patent owners in Brazil are under no obligation to provide know-how and raw materials

  • Kasznar Leonardos
  • Ler notícia